Oliver Lagore Vanvalin Investment Group’s Heart Test Laboratories HSCS Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio HSCS Stock Details HSCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-305	Closed	-$1.48K	–	703
2024 Q3	$1.48K	Sell	305 -180	-37%	-$658	﹤0.01%	597
2024 Q2	$2.53K	Sell	485 -219	-31%	-$1.74K	﹤0.01%	581
2024 Q1	$8.22K	Sell	704 -142	-17%	-$1.86K	﹤0.01%	439
2023 Q4	$14.5K	Buy	846 +150	+22%	+$3.69K	0.01%	362
2023 Q3	$29.7K	Sell	696 -433	-38%	-$33.6K	0.01%	296
2023 Q2	$102K	Sell	1,129 -437	-28%	-$42.7K	0.04%	171
2023 Q1	$155K	Sell	1,566 -52	-3%	-$7.03K	0.07%	101
2022 Q4	$136K	Buy	1,618 +1,368	+547%	+$214K	0.08%	106
2022 Q3	$30K	Buy	+250	New	+$42.7K	0.02%	215

Other funds holding HSCS

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's HSCS Position: Q4 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Heart Test Laboratories (HSCS) in Q4 2024, closing a stake of 305 shares — an estimated $1.48K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in HSCS in Q3 2022 and held it in 9 quarters. The position peaked at $155K in Q1 2023. 3 funds tracked by Wall St. Rank hold HSCS as of Q4 2024.

Oliver Lagore Vanvalin Investment Group reported no remaining Heart Test Laboratories position as of Q4 2024 after selling out during the quarter.
Oliver Lagore Vanvalin Investment Group sold 305 Heart Test Laboratories shares in Q4 2024, an estimated $1.48K.
Oliver Lagore Vanvalin Investment Group first reported a position in Heart Test Laboratories in Q3 2022 and held it in 9 quarters.
Oliver Lagore Vanvalin Investment Group's Heart Test Laboratories position peaked at $155K in Q1 2023.
3 funds tracked by Wall St. Rank held Heart Test Laboratories as of Q4 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2024, filed 1 Apr 2025.